ReviewCureus2024
Efficacy and Safety of Optilume Drug-Coated Balloon for Urethral Stricture Treatment: A Systematic Review and Meta-Analysis.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Efficacy of the optilume® drug-coated balloon for recurrent urethral stricture after prior urethroplasty: a 12-month multicenter follow-up study.World journal of urology · 2026Article
- Paclitaxel Drug-Coated Balloon (OptilumeMedicina (Kaunas, Lithuania) · 2026Review
- Drug-Coated Balloon (OptilumeAdvances in urology · 2026Article
- Article
- Efficacy and Mid-Term Outcomes of Paclitaxel-Coated Balloon (OptilumeJournal of clinical medicine · 2025Article
- Drug-Coated Balloon Treatment for Urethral Strictures: Is This the Future? A Review of the Current Literature.Journal of clinical medicine · 2025Review
- Optilume Drug-Coated Balloon for Acute Urinary Retention After Failed Treatment for Complex Recurrent Urethral Stricture Disease.Medicina (Kaunas, Lithuania) · 2025Article
- Drug-coated balloon dilation for female urethral stricture.Urology case reports · 2025Article
- 3D-bioprinted urethral grafts: Revolutionizing urethral stricture treatment.Arab journal of urology · 2025Review
- BEES-HAUS preventing urethral stricture recurrence by restoring the integrity of urothelium and its further simplified version, the BHES-HAUS.Frontiers in bioengineering and biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Optilume drug-coated balloon (DCB) (North Plymouth, USA) is a novel treatment option for urethral stricture disease that combines mechanical dilation with localized delivery of paclitaxel, an antiproliferative drug aimed at reducing recurrence rates by inhibiting scar tissue formation. This systematic review and meta-analysis, conducted using studies published in the last 10 years up to November 2024, assessed the efficacy and safety of Optilume DCB across seven studies involving 457 patients. Key outcomes included significant reductions in symptom scores, as measured by the International Prostate Symptom Score (IPSS), and improvements in urinary flow rates (QMax). The recurrence-free rate was approximately 80.83%, suggesting that Optilume offers durable symptom relief. The complication rate, calculated as a weighted average across studies, was low at 9.5%, with most adverse events being mild and temporary, including dysuria and urinary tract infections. These findings support Optilume DCB as a promising minimally invasive alternative to standard treatments, offering durable outcomes with a favorable safety profile. Further randomized trials with longer follow-ups are recommended to confirm these benefits in diverse patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.